Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of 7MW3711 in combination with a PD-1 Inhibitor, with or without antitumor therapies for the treatment of advanced solid tumors

Next Previous
Search
Trial Profile

A phase 1/2 study of 7MW3711 in combination with a PD-1 Inhibitor, with or without antitumor therapies for the treatment of advanced solid tumors

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 7MW 3711 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 09 Apr 2025 New trial record
    • 02 Apr 2025 According to a Mabwell (Shanghai) Bioscience media release, company announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with or without antitumor therapies, for the treatment of advanced solid tumors.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top